top of page

Frontier Medicines is leveraging a chemoproteomics platform to try to build a better KRAS G12C

Chris Varma describes why hitting KRAS G12C in both its on and off state could be an improvement over existing medicines. He also describes Frontier's platform and a recent $80M series C raise.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page